Transcatheter aortic valve replacement in 10 patients with hematologic neoplasms yielded minimal complications, improved cardiovascular function, and favorable 1-year survival.
Is transcatheter aortic valve replacement (TAVR) safe and feasible in patients with hematologic neoplasms and severe, symptomatic aortic stenosis?
TAVR appears to be a safe and feasible treatment option for patients with severe, symptomatic aortic stenosis and concomitant hematologic neoplasms.
Absolute Event Rate: 0% vs 0%
For patients with severe, symptomatic aortic stenosis (AS) who are poor surgical candidates, transcatheter aortic valve replacement (TAVR) offers a less invasive alternative to surgical valve replacement. Patients with hematologic neoplasms and severe AS are a high-risk subset, with increased risk of bleeding and infection, who have historically been excluded from clinical investigation in TAVR. Prior case reports have demonstrated successful TAVR in patients with hematologic neoplasms; however, there remains minimal literature on TAVR in this population. We present a series of 10 patients with hematologic neoplasms who underwent successful TAVR. Our cohort experienced minimal periprocedural complications and demonstrated marked improvement in cardiovascular function, with few long-term cardiac complications and favorable survival at 1 year post-procedure. These findings suggest that TAVR may be a feasible therapy in patients with concomitant hematologic neoplasms and severe, symptomatic AS.
Prinz et al. (Sun,) reported a other. Transcatheter aortic valve replacement in 10 patients with hematologic neoplasms yielded minimal complications, improved cardiovascular function, and favorable 1-year survival.